Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$827.78 USD

827.78
533,148

+11.13 (1.36%)

Updated Nov 7, 2024 03:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update

Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.

Regeneron (REGN) Gains But Lags Market: What You Should Know

In the latest trading session, Regeneron (REGN) closed at $747.33, marking a +1.38% move from the previous day.

Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.

Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales

Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.

Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know

Regeneron (REGN) closed the most recent trading day at $735.96, moving -0.01% from the previous trading session.

Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer

Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.

Neena Mishra headshot

Why Cash Rich Companies, ETFs are Beating the Market

We discuss Cash Cows & Trendpilot ETFs.

Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review

The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.

REGN vs. RGEN: Which Stock Is the Better Value Option?

REGN vs. RGEN: Which Stock Is the Better Value Option?

Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?

Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.

Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth

Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.

If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates

Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.

Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.

Ocular (OCUL) Announces Positive Data on Wet AMD Candidate

Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acuity.

AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe

AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.

Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe

The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.

Intellia (NTLA) Reports Positive Results for CRISPR Candidates

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).

Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.

Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.